NKNicolas Kerckhove

Nicolas Kerckhove

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nicolas Kerckhove has a total of 223 co-authors. Here are the top co-authors by number of shared publications:

  • Bruno Pereira

    Université Clermont Auvergne, INSERM, UMR 1107 – NEURO-DOL, CIC 1405, CHU Clermont-Ferrand, Service de Gastroentérologie, Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de l'Innovation, Clermont-Ferrand, France

    9 shared publications
  • Bruno Pereira

    DRCI, Unité de Biostatistiques, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France

    9 shared publications
  • David Balayssac

    Université Clermont Auvergne, Inserm U1107, Physiopathologie et pharmacologie de la douleur et de la migraine (NEURO-DOL), CHU de Clermont-Ferrand, Direction de la recherche clinique et de l’innovation

    8 shared publications
  • Chouki Chenaf

    Service de Pharmacologie Médicale, Direction de la Recherche Clinique et de L’Innovation, Université Clermont Auvergne, Clermont-Ferrand, France

    6 shared publications
  • Marie Selvy

    INSERM U1107 NEURO-DOL, CHU Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France

    6 shared publications
  • Nicolas Authier

    Centres Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Direction de la Recherche Clinique et de l’Innovation, Université Clermont Auvergne, CHU Clermont-Ferrand, UMR Inserm 1107-Neuro-Dol, Inserm CIC 1405, Service de Pharmacologie Médicale, Clermont-Ferrand, France

    6 shared publications

Latest Publications

  • Open Access

    Ethosuximide and Irritable Bowel Syndrome–Related Abdominal Pain

    by Nicolas Kerckhove, Frank Zerbib, Marion Chambaz, François Mion, Alberto Zalar, Felix Goutorbe, Benoit Coffin, Laure Payen, Sabine Roman, Anne Guilngar, et al.

    Importance: T-type calcium channels, particularly the Cav3.2 subtype, are involved in pain transduction. Experimental studies and human data suggested that increased T-type channels activity or expression contributes to visceral hypersensitivity in irritable bowel syndrome (IBS), and that their inhibition alleviates pain. Objective: To evaluate the therapeutic potential of ethosuximide, a T-type calcium channel blocker, for IBS-related abdominal pain. Design, Setting, and Participants: This proof-of-concept, multicenter, double-blinded, placebo-controlled randomized clinical trial started in February 2018 and completed in February 2022, with analyses performed between October 2023 and December 2024. Participants were adults meeting Rome IV criteria for IBS, treated in 10 gastroenterology departments in French university hospitals, with abdominal pain intensity rated at least 4 out of 10 during a 7-day run-in period. Interventions: Patients were randomized to receive ethosuximide or placebo daily for 12 weeks. Main Outcomes and Measures: The primary end point was the responder rate, defined as at least 30% reduction in mean abdominal pain intensity associated with a Subject Global Assessment of relief score at least 4 (ie, considerably or completely relieved). Secondary outcomes included safety, IBS symptom severity, and quality of life. Results: Of 161 enrolled patients, 124 were randomized (64 ethosuximide; 60 placebo). The mean (SD) age was 43.7 (14.9) years, 72 (58.1%) were women, the median (IQR) IBS duration was 5.0 (1.4-10.6) years, and the mean (SD) abdominal pain intensity was 6.0 (1.0). In the intent-to-treat analysis, responder rates did not differ significantly between groups (17 of 64 patients [26.6%] for ethosuximide vs 14 of 60 patients [23.3%] for placebo; relative risk, 1.14; 95% CI, 0.61-2.11). Ethosuximide was less well tolerated, with higher discontinuation rates (30 patients [46.9%] vs 13 patients [21.7%]; P = .003) and more adverse events (261 of 463 adverse events reported overall [56.4%] were determined to be caused by ethosuximide; P < .001), most commonly headaches, sleep disturbances, and nausea, compared with placebo. Conclusions and Relevance: In this randomized clinical trial, ethosuximide did not demonstrate efficacy over placebo for the treatment of IBS-related abdominal pain, and was associated with reduced tolerability. These findings do not support the use of ethosuximide for IBS pain management but highlight the need for development of more selective and better-tolerated T-type calcium channel modulators. Trial Registration: ClinicalTrials.gov Identifier: NCT02973542

  • Open Access

    Buprenorphine Substitution as a Tapering Strategy for Opioid Discontinuation in Patients with Chronic Pain: A Nonrandomized and Proof of Concept Study

    by Célian Bertin, Nicolas Kerckhove, Florent Ferrer, Bruno Pereira, Christian Duale, Damien Richard, Nicolas Authier, Noémie Delage

    Introduction Long-term use (≥ 3 months) of opioids for chronic noncancer pain (CNCP) shows limited benefit and often leads to dependence, especially when tapered too quickly. Standard opioid discontinuation typically involves gradual dose reduction, yet many patients fail to complete it. Meta-analyses show buprenorphine reduces withdrawal severity, increases treatment retention and completion rates, and facilitates analgesia and smoother transitions in patients with chronic pain, with low adverse effects and high initiation success. Methods This single-center, prospective, nonrandomized proof-of-concept study assessed the efficacy of an outpatient buprenorphine-based discontinuation strategy in patients with CNCP and opioid dependence who had failed standard tapering. Participants first attempted gradual tapering; those unsuccessful transitioned to buprenorphine: 4–8 mg/day for 1 month, followed by tapering over up to 9 months. Success was defined as complete opioid cessation at 9 months, confirmed by urine analysis (including buprenorphine). The primary outcome was the success rate of the buprenorphine strategy, with ≥ 60% considered effective. A secondary outcome compared success rates between strategies. Results Of 20 patients, six (30.0%) successfully withdrew using standard tapering. Fourteen failed; 11 of them transitioned to buprenorphine. Of these, seven (63.6%) achieved full discontinuation. While not statistically significant, the buprenorphine group showed a higher success rate than standard tapering (p = 0.076; OR = 4.08 [0.90–21.23]). Conclusions Buprenorphine substitution appears at least as effective as conventional tapering and may benefit patients unable to succeed with tapering alone. These preliminary results support further investigation in larger trials. Trial Registration ClinicalTrials. gov identifier, NCT03156907.

  • Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life

    by David Balayssac, Nicolas Kerckhove, Marie Selvy, Bruno Pereira, Coralie Gonneau, Caroline Pétorin, Agnès Vimal-Baguet, Sergey Melnikov, Sharif Kullab, Mohamed Hebbar, et al.

    Purpose Sensory chemotherapy-induced peripheral neuropathy (CIPN) is well-recognized, but motor CIPN remains understudied. This secondary analysis focused on the long-term severity and impact of motor disorders, their relation to sensory CIPN, neuropathic pain, psychological distress, and health-related quality of life (HRQoL) after oxaliplatin-based chemotherapy in colorectal cancer (CRC) survivors. Methods Data from a multicenter, cross-sectional study were re-analyzed to explore motor CIPN among CRC survivors up to 5 years post-chemotherapy, with no longitudinal follow-up. Questionnaires assessed sensory and motor CIPN (QLQ-CIPN20), neuropathic pain (DN4), anxiety and depression (HADS), and HRQoL (QLQ-C30). Results Among 405 CRC survivors, 31.1% had sensory CIPN as previously described. When categorizing the 405 CRC survivors based on the years since their last oxaliplatin-based chemotherapy, the motor scores derived from the QLQ-CIPN20 showed no significant difference between years (p = 0.08). Motor CIPN scores correlated with female gender, higher oxaliplatin dose intensity, sensory CIPN, and neuropathic pain. Motor CIPN also linked to decreased HRQoL and increased psychological distress. Conclusion The study underscores the detrimental impact of motor disorders on CRC survivors post-oxaliplatin-based chemotherapy. Oncologists should prioritize assessing and managing motor manifestations alongside sensory symptoms to enhance post-cancer quality of life. Trial registration: NCT02970526 (2016-11-22). https://classic.clinicaltrials.gov/ct2/show/NCT02970526?term=NCT02970526&draw=2&rank=1.


  • Open Access

    Mobile Health App and Web Platform (eDOL) for Medical Follow-Up of Patients With Chronic Pain: Cohort Study Involving the French eDOL National Cohort After 1 Year

    by Noémie Delage, Nathalie Cantagrel, Sandrine Soriot-Thomas, Marie Frost, Rodrigue Deleens, Patrick Ginies, Alain Eschalier, Alice Corteval, Alicia Laveyssière, Jules Phalip, et al.

    Background: Chronic pain affects approximately 30% of the general population, severely degrades quality of life and professional life, and leads to additional health care costs. Moreover, the medical follow-up of patients with chronic pain remains complex and provides only fragmentary data on painful daily experiences. This situation makes the management of patients with chronic pain less than optimal and may partly explain the lack of effectiveness of current therapies. Real-life monitoring of subjective and objective markers of chronic pain using mobile health (mHealth) programs could better characterize patients, chronic pain, pain medications, and daily impact to help medical management. Objective: This cohort study aimed to assess the ability of our mHealth tool (eDOL) to collect extensive real-life medical data from chronic pain patients after 1 year of use. The data collected in this way would provide new epidemiological and pathophysiological data on chronic pain. Methods: A French national cohort of patients with chronic pain treated at 18 pain clinics has been established and followed up using mHealth tools. This cohort makes it possible to collect the determinants and repercussions of chronic pain and their evolutions in a real-life context, taking into account all environmental events likely to influence chronic pain. The patients were asked to complete several questionnaires, body schemes, and weekly meters, and were able to interact with a chatbot and use educational modules on chronic pain. Physicians could monitor their patients’ progress in real time via an online platform. Results: The cohort study included 1427 patients and analyzed 1178 patients. The eDOL tool was able to collect various sociodemographic data; specific data for characterizing pain disorders, including body scheme; data on comorbidities related to chronic pain and its psychological and overall impact on patients’ quality of life; data on drug and nondrug therapeutics and their benefit-to-risk ratio; and medical or treatment history. Among the patients completing weekly meters, 49.4% (497/1007) continued to complete them after 3 months of follow-up, and the proportion stabilized at 39.3% (108/275) after 12 months of follow-up. Overall, despite a fairly high attrition rate over the follow-up period, the eDOL tool collected extensive data. This amount of data will increase over time and provide a significant volume of health data of interest for future research involving the epidemiology, care pathways, trajectories, medical management, sociodemographic characteristics, and other aspects of patients with chronic pain. Conclusions: This work demonstrates that the mHealth tool eDOL is able to generate a considerable volume of data concerning the determinants and repercussions of chronic pain and their evolutions in a real-life context. The eDOL tool can incorporate numerous parameters to ensure the detailed characterization of patients with chronic pain for future research and pain management. Trial Registration: ClinicalTrials.gov NCT04880096; https://clinicaltrials.gov/ct2/show/NCT04880096


  • Open Access

    Mobile Health App and Web Platform (eDOL) for Medical Follow-Up of Patients With Chronic Pain: Cohort Study Involving the French eDOL National Cohort After 1 Year (Preprint)

    by Noémie Delage, Nathalie Cantagrel, Sandrine Soriot-Thomas, Marie Frost, Rodrigue Deleens, Patrick Ginies, Alain Eschalier, Alice Corteval, Alicia Laveyssière, Jules Phalip, et al.

    BACKGROUND Chronic pain affects approximately 30% of the general population, severely degrades quality of life and professional life, and leads to additional health care costs. Moreover, the medical follow-up of patients with chronic pain remains complex and provides only fragmentary data on painful daily experiences. This situation makes the management of patients with chronic pain less than optimal and may partly explain the lack of effectiveness of current therapies. Real-life monitoring of subjective and objective markers of chronic pain using mobile health (mHealth) programs could better characterize patients, chronic pain, pain medications, and daily impact to help medical management. OBJECTIVE This cohort study aimed to assess the ability of our mHealth tool (eDOL) to collect extensive real-life medical data from chronic pain patients after 1 year of use. The data collected in this way would provide new epidemiological and pathophysiological data on chronic pain. METHODS A French national cohort of patients with chronic pain treated at 18 pain clinics has been established and followed up using mHealth tools. This cohort makes it possible to collect the determinants and repercussions of chronic pain and their evolutions in a real-life context, taking into account all environmental events likely to influence chronic pain. The patients were asked to complete several questionnaires, body schemes, and weekly meters, and were able to interact with a chatbot and use educational modules on chronic pain. Physicians could monitor their patients’ progress in real time via an online platform. RESULTS The cohort study included 1427 patients and analyzed 1178 patients. The eDOL tool was able to collect various sociodemographic data; specific data for characterizing pain disorders, including body scheme; data on comorbidities related to chronic pain and its psychological and overall impact on patients’ quality of life; data on drug and nondrug therapeutics and their benefit-to-risk ratio; and medical or treatment history. Among the patients completing weekly meters, 49.4% (497/1007) continued to complete them after 3 months of follow-up, and the proportion stabilized at 39.3% (108/275) after 12 months of follow-up. Overall, despite a fairly high attrition rate over the follow-up period, the eDOL tool collected extensive data. This amount of data will increase over time and provide a significant volume of health data of interest for future research involving the epidemiology, care pathways, trajectories, medical management, sociodemographic characteristics, and other aspects of patients with chronic pain. CONCLUSIONS This work demonstrates that the mHealth tool eDOL is able to generate a considerable volume of data concerning the determinants and repercussions of chronic pain and their evolutions in a real-life context. The eDOL tool can incorporate numerous parameters to ensure the detailed characterization of patients with chronic pain for future research and pain management. CLINICALTRIAL ClinicalTrials.gov NCT04880096; https://clinicaltrials.gov/ct2/show/NCT04880096

  • Open Access

    Chronic pain is a risk factor for incident Alzheimer’s disease: a nationwide propensity-matched cohort using administrative data

    by Nadège Bornier, Aurélien Mulliez, Chouki Chenaf, Antoine Elyn, Sarah Teixeira, Nicolas Authier, Célian Bertin, Nicolas Kerckhove

    Introduction: Chronic pain (CP) is one of the most disabling conditions in the elderly and seems to be a risk factor for the development of Alzheimer’s disease and related dementias (ADRD). Only one study, using national administrative health databases, assessed and demonstrated that chronic pain (all types of pain) was a risk factor for dementia, but without assessing the impact of pain medications.Method: To assess the impact of all types of chronic pain and the long-term use of pain medications on the person-years incidence of ADRD, a retrospective nationwide healthcare administrative data study was performed using the national inter-regime health insurance information system (SNIIRAM) to the French national health data system (SNDS). Incident people >50 years old with chronic pain, defined by at least 6-months duration analgesics treatment or by a diagnosis/long-term illness of chronic pain between 2006 and 2010, were included. Chronic pain individuals were matched with non-CP individuals by a propensity score. Individuals were followed up from 9 to 13 years to identify occurrences of ADRD from 2006.Results: Among 64,496 French individuals, the incidence of ADRD was higher in the chronic pain population than control (1.13% vs. 0.95%, p <0.001). Chronic pain increases the risk of ADRD (HR = 1.23) and the incidence of ADRD was higher for women and increased significantly with age.Discussion: Our study highlights the importance of prevention, diagnosis, and management of chronic pain in elderly to reduce the risk of development and/or worsening of dementia.


  • Prevalence of Chronic Pain Among People with Dementia: A Nationwide Study Using French Administrative Data

    by Nicolas Kerckhove, Nadège Bornier, Aurélien Mulliez, Antoine Elyn, Sarah Teixeira, Nicolas Authier, Célian Bertin, Chouki Chenaf


  • Open Access

    Real-Life Testing of the Prescription Opioid Misuse Index in French Primary Care

    by Catherine Laporte, Frédéric Fortin, Julie Dupouy, Aurélie Quirin, Bruno Pereira, Chouki Chenaf, Jessica Delorme, Christine Maynié-François, Cédric Rat, Jordan Birebent, et al.

    Analgesic opioid (AO) misuse by patients ranges from 0% to 50%. General practitioners are the first prescribers of AO. Our objective was to validate the Prescription Opioid Misuse Index (POMI) in primary care. We conducted a psychometric study in patients with chronic pain who had been taking AOs for at least 3 months and were followed in general practice. Patients responded to the POMI at inclusion and after 2 weeks. The reference used was the DSM-V. Sixty-nine GPs included 160 patients (87 women, 54.4%), mean age 56.4 ± 15.2 years. The total POMI score was 1.50 ± 1.27, and 73/160 (45.6.0%) had a score ≥ 2 (misuse threshold). Internal validity was measured with the Kuder–Richardson coefficient, which was 0.44. Correlations between each item and the total score ranged from 0.06 to 0.35. Test–retest reliability was determined from 145 patients: Lin’s concordance coefficient was 0.57 [0.46, 0.68]. Correlation with the DSM-V (Spearman’s coefficient) was 0.52. The POMI does not have sufficient psychometric properties to be recommended as a tool to identify the misuse of AOs in primary care. This study clearly showed that there is a need to create a monitoring tool specific to primary care.


  • Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy

    by Jessica Delorme, Nicolas Kerckhove, Nicolas Authier, Bruno Pereira, Célian Bertin, Chouki Chenaf


  • Open Access

    Cross-sectional study of the prevalence of prescription opioids misuse in French patients with chronic non-cancer pain: An update with the French version of the POMI scale

    by Nicolas Kerckhove, Noémie Delage, Célian Bertin, Emmanuelle Kuhn, Nathalie Cantagrel, Caroline Vigneau, Jessica Delorme, Céline Lambert, Bruno Pereira, Chouki Chenaf, et al.

    Public health issues related to chronic pain management and the risks of opioid misuse and abuse remain a challenge for practitioners. Data on the prevalence of disorders related to the use of prescribed opioids in patients suffering from chronic pain remains rather patchy, in particular because of the absence of a gold standard for their clinical assessment. We estimated the prevalence of prescription opioid misuse (POM), using a specific and validated opioid misuse scale (POMI-5F scale), in adults with chronic non-cancer pain. Nine-hundred-fifty-one (951) patients with opioids prescription and followed-up in pain clinics and addictology centers for chronic non-cancer pain (CNCP) completed the survey interview. The results suggest that 44.4% of participants have POM, accompanied by overuse (42.5%), use of opioids for effects other than analgesia (30.9%), withdrawal syndrome (65.7%), and craving (6.9%). The motivations cited for POM, apart from pain relief, were to calm down, relax and improve mood. POM was shown to be related to male sex (OR 1.52), young age (OR 2.21) and the presence of nociplastic pain (OR 1.62) of severe intensity (OR 2.31), codeine use (OR 1.72) and co-prescription of benzodiazepines (OR 1.59). Finally, despite the presence of three subgroups of misusers, no factor was associated with the intensity of misuse, reinforcing the view that distinguishing between strong and weak opioids is not appropriate in the context of use disorder. Almost half of patients with CNCP misuse their prescribed opioid. Practitioners should be attentive of profiles of patients at risk of POM, such as young, male patients suffering from severe nociplastic pain, receiving prescription for codeine and a co-prescription for benzodiazepine. We encourage French-speaking practitioners to use the POMI-5F scale to assess the presence of POM in their patients receiving opioid-based therapy.Clinical Trial Registrationclinicaltrials.gov, identifier NCT03195374